| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 109.51% | Wells Fargo | → $1 | Downgrades | Overweight → Equal-Weight |
| 11/03/2023 | 319.02% | RBC Capital | $6 → $2 | Downgrades | Outperform → Sector Perform |
| 08/15/2023 | 1366.58% | Truist Securities | $8 → $7 | Maintains | Buy |
| 08/14/2023 | 947.56% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 1995.12% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 738.05% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 1785.61% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 1157.07% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 1576.09% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 947.56% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 214.27% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 3042.68% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 3252.19% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 2623.65% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 3042.68% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 4090.24% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 947.56% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 3880.72% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 4509.26% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 3252.19% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 5137.8% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 4090.24% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 4509.26% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 2833.17% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 2204.63% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 2204.63% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
What is the target price for Sangamo Therapeutics (SGMO)?
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Wells Fargo on November 6, 2023. The analyst firm set a price target for $1.00 expecting SGMO to rise to within 12 months (a possible 109.51% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Wells Fargo, and Sangamo Therapeutics downgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a downgraded with a price target of $0.00 to $1.00. The current price Sangamo Therapeutics (SGMO) is trading at is $0.48, which is within the analyst's predicted range.